To access this content, you must be a member. Visit the Plans page for details.
8% of 13F filers add to Valeant positions in Q3
As Valeant Pharmaceutical shares slid 28% in Q3, some hedge funds saw it as a buying opportunity. Whalewisdom finds that [Read More]